US Senate panel adopts biosimilars bill with 12-year exclusivity
15 July 2009
Sue Sutter
Please Login to read the full article.
15 July 2009
Sue Sutter
The US Senate health (HELP) committee's approval of a biosimilars measure with 12 years of innovator exclusivity hands the biotechnology and pharmaceutical industries a significant victory in the face of stances taken by a powerful House Democrat and the Obama Administration that the data...
Please Login to read the full article.
RELATED CONTENT
NEWS
- After rancorous 2011, BIO expects some congressional rematches in 2012
- US Capitol Capsule: Hope not enough for Avastin in MBC; Hamburg explains withdrawal
- US Capitol Capsule: House adopts patent reform, but fee change could be trouble for Senate
- US Capitol Capsule: Will pharma get fried in the debt ceiling chicken game?
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
